KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Asset Utilization Ratio (2016 - 2025)

Alnylam Pharmaceuticals' Asset Utilization Ratio history spans 16 years, with the latest figure at 0.64 for Q4 2025.

  • For Q4 2025, Asset Utilization Ratio rose 20.51% year-over-year to 0.64; the TTM value through Dec 2025 reached 0.64, up 20.51%, while the annual FY2025 figure was 0.81, 44.8% up from the prior year.
  • Asset Utilization Ratio reached 0.64 in Q4 2025 per ALNY's latest filing, up from 0.56 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.64 in Q4 2025 to a low of 0.17 in Q1 2021.
  • Average Asset Utilization Ratio over 5 years is 0.39, with a median of 0.39 recorded in 2023.
  • Peak YoY movement for Asset Utilization Ratio: skyrocketed 78.84% in 2021, then fell 27.77% in 2025.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.24 in 2021, then rose by 23.47% to 0.29 in 2022, then surged by 62.74% to 0.48 in 2023, then increased by 11.67% to 0.53 in 2024, then rose by 20.51% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Asset Utilization Ratio are 0.64 (Q4 2025), 0.56 (Q3 2025), and 0.43 (Q2 2025).